Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a medicaid fee-for-service population

Journal of Managed Care Pharmacy

Volumn 12, Issue 2, 2006, Pages 121-129

  Kalsekar, Iftekhar ^a   Iyer, Shrividya ^b   Mody, Reema ^d   Rajagopalan, Rukmini ^c   Kavookjian, Jan ^e  

^a BUTLER UNIVERSITY   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

^c Health Economics and Statistics   (United States)

^d TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^e WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Claims data; Costs; Insulin; Medicaid; Thiazolidinediones

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BIGUANIDE DERIVATIVE; CARDIOVASCULAR AGENT; INSULIN; MEGLITINIDE; NITRATE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BILLING AND CLAIMS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DRUG COST; DRUG UTILIZATION; EMERGENCY WARD; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICAL FEE; MICROANGIOPATHY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PERIPHERAL VASCULAR DISEASE; PHARMACY; PRESCRIPTION; RETINOPATHY; COMPARATIVE STUDY; ECONOMICS; HEALTH CARE COST; HEALTH SERVICE; INSURANCE; MIDDLE AGED; POLYPHARMACY; UTILIZATION REVIEW;

DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION; FEE-FOR-SERVICE PLANS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSURANCE CLAIM REVIEW; MALE; MEDICAID; MIDDLE AGED; PATIENT COMPLIANCE; POLYPHARMACY; THIAZOLIDINEDIONES;

EID: 33745506293     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.2.121     Document Type: Article

References (37)

1. National Diabetes Information Clearinghouse (2003). National Diabetes Statistics. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Accessed May 5, 2004.
2. American Diabetes Association: Economic costs of diabetes mellitus in the US in 2002. Diabetes Care. 2003;26(3):917-32.
3. Selby JV, Ray GT, Zhang D, et al. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care. 1997;20:1396-1402.
4. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 2003;352:837-53.
5. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes a preliminary report. Diabetes Care. 2004;27:17-20.
6. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med. 2004;116:230-35.
7. Dailey GE, Noor MA, Park JS, et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med. 2004;116:223-29.
8. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106-18.
9. Rosenbaum MS, Kane MP. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus. J Manag Care Pharm. 2003;9(4):309-16.
10. Costa B, Arroyo J, Sabate A. The economics of pharmacotherapy for diabetes. Pharmacoeconomics. 1997;11(2):139-58.
11. Dailey GE. Early insulin: An important therapeutic strategy. Diabetes Care. 2005;28(1):220-21.
12. Marre M. Before oral agents fail: the case for starting insulin early. Int J Obes. 2002;26(suppl 3):S25-S30.
13. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: Effectiveness, complications and resource utilization. JAMA. 1997;278 (20):1663-69.
14. Maciejewski ML and Maynard C. Diabetes-related utilization and costs for inpatient and outpatient services in the Veterans Administration. Diabetes Care. 2004;27(suppl 2):B69-B73.
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in IDDM. N Engl J Med. 1993;329:977-86.
16. Anderson RM, Hess GE, Davis WK, Hiss RG. Community diabetes care in the 1980s. Diabetes Care. 1988;11:519-26.
17. Coyle D, Palmer AJ, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes in Canada. Pharmacoeconomics. 2002;20:S31-S42.
18. Chilcott J, Wight J, Lloyd Jones M, Tappenden P. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review. Health Technol Assess. 2001;5(19):1-61.
19. Motheral BR, Fairman KA. The use of claims databases for outcomes research: Rationale, challenges, and strategies. Clin Ther. 1997;19(2):346-66.
20. Quinn L. Pharmacologic management of the patient with type 2 diabetes. Nurs Clin North America. 2001;36(2):217-42.
21. Consumer Price Index. Available at: http://www.bls.gov/cpi/home.htm. Accessed May 6, 2004.
22. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41-55.
23. Efron B, Tibshirani RJ. An Introduction to Bootstrap. New York: Chapman and Hall; 1993.
24. Desgagne A, Castilloux AM, Angers JF, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics. 1998;13(5):487-97.
25. Mooney CZ, Duval RD. Bootstrapping: A Non-Parametric Approach to Statistical Interference. Beverly Hills, CA: Sage Publications; 1993.
26. Brown RR. Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes. Am J Health Syst Pharm. 1998;55(suppl 4):S24-S27.
27. Nilsson A, Tideholm B, Kalen J, Katzman P. Incidence of severe hypoglycemia and its causes in insulin-treated diabetics. Acta Med Scand. 1988;224(3):257-62.
28. Heaton A, Martin S, Brelje T. The economic effect of hypoglycemia in a health plan. Manag Care Interface. 2003;16(7):23-27.
29. Ferrannini E, Haffner SM, Mitchell BD, et al. Hyperinsulinaemia: the key feature of cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416-22.
30. Houtzagers CMG, Berntzen PA, Van der Stap H, et al. Efficacy and acceptance of two intensified conventional insulin therapy regimens: a long-term cross-over comparison. Diabet Med. 1989;6:416-21.
31. Montgomery BJ 1979. High plasma insulin level a prime risk factor for heart disease. JAMA. 1979;241(16):1665.
32. Stout RW 1981. The role of insulin in atherosclerosis in diabetics and nondiabetics: a review. Diabetes. 1981;30(suppl 2):54-57.
33. Stout RW 1990. Insulin and atheroma. 20-yr. perspective. Diabetes Care. 1990;13(6):631-54.
34. Parulkar AA, Pendergrass ML, Granda-Ayal R, Lee TR, Gonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;134:61-71.
35. Koro CE, Fu Q, Dirani RG, Fedder DO. Beneficial effects of thiazolidinediones on myocardial infarction risk in patients with type 2 diabetes. Program and abstracts presented at: 64th Scientific Sessions of the American Diabetes Association; June 4-8, 2004; Orlando, FL. Abstract 1009-P.
36. Currie CJ, Morgan CL, Peters JR. Patterns and costs of hospital care for coronary heart disease related and not related to diabetes. Heart. 1997;78(6):544-49.
37. Gagliardino JJ, Martella A, Erchegoyen GS et al. Hospitalization and re-hospitalization of people with and without diabetes in La Plata, Argentina: comparison of their clinical characteristics and costs. Diabetes Res Clin Prac. 2004;65:51-59.